Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating the Safety and Efficacy of IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Subjects With Borderline Resectable Pancreatic Cancer

NCT07415525 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT07415525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07415525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating the Safety and Efficacy of IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Subjects With Borderline Resectable Pancreatic Cancer
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
December 31, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma, pancreatic cancer